The Lancet Oncology 今日热榜



The Lancet Oncology The Lancet Oncology

1.	[Policy Review] Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements	Javier E Villanueva-Meyer, Spyridon Bakas, Pallavi Tiwari, Janine M Lupo, Evan Calabrese, Christos Davatzikos, Wenya Linda Bi, Marwa Ismail, Hamed Akbari, Philipp Lohmann, Thomas C Booth, Benedikt Wiestler, Hugo J W L Aerts, Ghulam Rasool, Joerg C Tonn, Martha Nowosielski, Rajan Jain, Rivka R Colen, Sarthak Pati, Ujjwal Baid, Philipp Vollmuth, David Macdonald, Michael A Vogelbaum, Susan M Chang, Raymond Y Huang, Norbert Galldiks, Response Assessment in Neuro Oncology (RANO) group	
2.	[Articles] Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data	Marie Lund, Giulia Corn, Maj-Britt Jensen, Tonny Petersen, Kim Dalhoff, Bent Ejlertsen, Lars Køber, Jan Wohlfahrt, Mads Melbye	
3.	[Policy Review] Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice	Spyridon Bakas, Philipp Vollmuth, Norbert Galldiks, Thomas C Booth, Hugo J W L Aerts, Wenya Linda Bi, Benedikt Wiestler, Pallavi Tiwari, Sarthak Pati, Ujjwal Baid, Evan Calabrese, Philipp Lohmann, Martha Nowosielski, Rajan Jain, Rivka Colen, Marwa Ismail, Ghulam Rasool, Janine M Lupo, Hamed Akbari, Joerg C Tonn, David Macdonald, Michael Vogelbaum, Susan M Chang, Christos Davatzikos, Javier E Villanueva-Meyer, Raymond Y Huang, Response Assessment in Neuro Oncology (RANO) group	
4.	[Correspondence] PSMA-PET research: addressing challenges and prospects – Authors' reply	Boris A Hadaschik, Madeleine J Karpinski, Johannes Hüsing, Wolfgang P Fendler	
5.	[Editorial] Caring for carers of people with cancer	The Lancet Oncology	
6.	[Articles] Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial	Mafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, Erika Hamilton, Yaroslav Kulyaba, Timur Andabekov, Yevhen Hotko, Tamar Melkadze, Gia Nemsadze, Patrick Neven, Vladimir Vladimirov, Claudio Zamagni, Hannelore Denys, Frédéric Forget, Zsolt Horvath, Alfiya Nesterova, Maxine Ajimi, Bistra Kirova, Teresa Klinowska, Justin P O Lindemann, Delphine Lissa, Alastair Mathewson, Christopher J Morrow, Zuzana Traugottova, Ruaan van Zyl, Ekaterine Arkania	
7.	[Correspondence] Concerns regarding the AtTEnd trial in advanced endometrial carcinoma	Queran Lin, Wenyi Jin, Dan Shan	
8.	[Correspondence] PSMA-PET research: addressing challenges and prospects	Hantong Hu	
9.	[Correspondence] PSMA-PET research: addressing challenges and prospects	Dan Shan	
10.	[Correspondence] Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer?	Ryan Huey, Kanwal Raghav	
11.	[Correspondence] Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer? – Authors' reply	Xichun Hu, Shiyu Jiang, Xin Liu	
12.	[Correspondence] Celiac plexus radiosurgery for retroperitoneal pain syndrome – Authors' reply	Yaacov R Lawrence, Ronen Fluss, Laurence S Freedman, Zvi Symon	
13.	[Correspondence] Celiac plexus radiosurgery for retroperitoneal pain syndrome	Ertugrul Senturk, Serap Catli Dinc	
14.	[Corrections] Correction to Lancet Oncol 2024; 25: 1453–64		
15.	[Correspondence] Concerns regarding the AtTEnd trial in advanced endometrial carcinoma	Ze Xiang, Jian Wu	
16.	[Comment] The state of the science of oral selective oestrogen receptor degraders	Kristina Fanucci, Erica L Mayer	
17.	[Corrections] Correction to Lancet Oncol 2024; 25: 1325–36		
18.	[Correspondence] [18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer – Authors' reply	Sébastien Thureau, Philippe Giraud, Gérard Zalcman, Pierre Vera	
19.	[Correspondence] Concerns regarding the AtTEnd trial in advanced endometrial carcinoma – Authors' reply	Elena Biagioli, Eliana Rulli, Roldano Fossati, Nicoletta Colombo	
20.	[Correspondence] [18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer	Sarah Bowen Jones, Saskia Cooke, José Belderbos, Corinne Faivre-Finn	
21.	[Correspondence] [18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer	Xiaoling Xu, Lisha Ye, Jinpeng Shi, Huihui Li, Yong Fang	
22.	[Correspondence] Omitting study limitations might have implications for the patients – Authors' reply	Jean-Yves Blay, Sylvie Chabaud, David Perol, Axel Le Cesne	
23.	[Correspondence] Omitting study limitations might have implications for the patients	Paul de Boissieu, Sylvie Chevret	
24.	[Articles] Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis	Antonio D'Alessio, Bernardo Stefanini, Julia Blanter, Benjamin Adegbite, Fionnuala Crowley, Vincent Yip, Sarah Slater, Claudia Angela Maria Fulgenzi, Ciro Celsa, Giulia Francesca Manfredi, Madhava Pai, Robert D Goldin, Stephen C Ward, Maria Isabel Fiel, Daniel H Shu, Yung-Yeh Su, Alessio Cortellini, Marina Baretti, Robert Anders, Mark Yarchoan, Chiun Hsu, Thomas U Marron, David J Pinato	
25.	[News] US legislation might soon allow easier access to cancer medications	Karl Gruber	
26.	[News] Renewed collaboration aims to improve cancer outcomes in South America	Manjulika Das	
27.	[Perspectives] Cancer control in the Commonwealth: a roadmap	Rifat Atun, Bhawna Sirohi, Che Reddy, Mary Gospodarowicz	
28.	[Articles] Access to diagnostic imaging and radiotherapy technologies for patients with cancer in the Baltic countries, eastern Europe, central Asia, and the Caucasus: a comprehensive analysis	Manjit Dosanjh, Vesna Gershan, Eugenia C Wendling, Jamal S Khader, Taofeeq A Ige, Mimoza Ristova, Richard Hugtenburg, Petya Georgieva, C Norman Coleman, David A Pistenmaa, Gohar H Hovhannisyan, Tatul Saghatelyan, Kamal Kazimov, Rovshan Rzayev, Gulam R Babayev, Mirzali M Aliyev, Eduard Gershkevitsh, Irina Khomeriki, Lily Petriashvili, Maia Topeshashvili, Raushan Zakirova, Aigerim Rakhimova, Natalya Karnakova, Aralbaev Rakhatbek, Narynbek Kazybaev, Oksana Bondareva, Kristaps Palskis, Gaļina Boka, Erika Korobeinikova, Linas Kudrevicius, Ion Apostol, Ludmila V Eftodiev, Alfreda Rosca, Galina Rusnac, Mukhabatsho Khikmatov, Sergii Luchkovskyi, Yuliia Severyn, Jamshid M Alimov, Munojat Ismailova, Suvsana M Talibova	
29.	[Articles] Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial	Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García Campelo, Joaquín Casal, Manuel Dómine, Bartomeu Massuti, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier de Castro, David Gómez de Antonio, Iván Macia, Santiago Figueroa, Luís Fernández Vago, Virginia Calvo, Ramón Palmero, Belén Sierra-Rodero, Cristina Martínez-Toledo, Marta Molina-Alejandre, Roberto Serna-Blasco, Atocha Romero, Alberto Cruz-Bermúdez	
30.	[Personal View] Interchangeability of immune checkpoint inhibitors: an urgent need for action	Michiel Zietse, Roelof W F van Leeuwen, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Jolanda E de Boer, Rudy Dupree, Ron H J Mathijssen, Lonneke Timmers	
31.	[Corrections] Correction to Lancet Oncol 2024; 25: 1310–24		
32.	[News] Abortion restrictions have a negative impact on cancer care	Sharmila Devi	
33.	[News] The Biden administration curbs cancer drug costs for Medicare patients	Bryant Furlow	
34.	[News] UK NHS cancer patients to be among those benefiting from deal with life sciences industry	Tony Kirby	
35.	[Comment] The hidden barriers to using cancer registration data	Nicola Hughes, Richard Feltbower, Dan Stark	
36.	[Articles] Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis	Ashley Jackson, Pradeep S Virdee, Sharon Tonner, Jason L Oke, Rafael Perera, Kaveh Riahi, Ying Luan, Sara Hiom, Harpal Kumar, Harit Nandani, Kathryn N Kurtzman, Dyfed Huws, Dawn Allan, Stephanie Smits, Sean McPhail, Eileen E Parkes, F D Richard Hobbs, Mark R Middleton, Brian D Nicholson	
37.	[Articles] Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis	Harriet Rumgay, Suzanne T Nethan, Richa Shah, Jérôme Vignat, Olalekan Ayo-Yusuf, Pankaj Chaturvedi, Eliete N S Guerra, Prakash C Gupta, Ruchika Gupta, Shiwei Liu, Cecilia Magnusson, Mark Parascandola, Yvette C Paulino, Negar Rezaei, Kamran Siddiqi, Saman Warnakulasuriya, Beatrice Lauby-Secretan, Isabelle Soerjomataram	
38.	[News] ASTRO 2024 Annual Meeting	Smriti Patodia	
39.	[Articles] Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy study	Dianna L Ng, Edda Vuhahula, Asteria H Kimambo, Marie Claire Ndayisaba, Godfrey S Philipo, Beatrice P Mushi, Kenneth E Ho, Alan Paciorek, Zainab Illonga, Li Zhang, Poonam Vohra, Jodi Weidler, Michael Bates, Elia J Mmbaga, Katherine Van Loon	
40.	[News] Approval of single-use e-cigarettes ban in France	Manjulika Das	
41.	[News] Jordan joins the Global Platform for Access to Childhood Cancer Medicines	Elizabeth Gourd	
42.	[Corrections] Correction to Lancet Oncol 2024; 25: 1371–86		
43.	[Corrections] Correction to Lancet Oncol 2024; 25: 1357–70		
44.	[Comment] Focus where it matters: turning insights into advocacy	John Christodouleas, Therese Lindé, Gustaf Salford	
45.	[Comment] Radiotherapy and conflict: from disruption to expansion and hope	Nazik Hammad, Fidel Rubagumya	
46.	[The Lancet Oncology Commission] Radiotherapy and theranostics: a Lancet Oncology Commission	May Abdel-Wahab, Francesco Giammarile, Mauro Carrara, Diana Paez, Hedvig Hricak, Nayyereh Ayati, Jing Jing Li, Malina Mueller, Ajay Aggarwal, Akram Al-Ibraheem, Sondos Alkhatib, Rifat Atun, Abubakar Bello, Daniel Berger, Roberto C Delgado Bolton, John M Buatti, Graeme Burt, Olivera Ciraj Bjelac, Lisbeth Cordero-Mendez, Manjit Dosanjh, Thomas Eichler, Elena Fidarova, Soehartati Gondhowiardjo, Mary Gospodarowicz, Surbhi Grover, Varsha Hande, Ekaterina Harsdorf-Enderndorf, Ken Herrmann, Michael S Hofman, Ola Holmberg, David Jaffray, Peter Knoll, Jolanta Kunikowska, Jason S Lewis, Yolande Lievens, Miriam Mikhail-Lette, Dennis Ostwald, Jatinder R Palta, Platon Peristeris, Arthur A Rosa, Soha Ahmed Salem, Marcos A dos Santos, Mike M Sathekge, Shyam Kishore Shrivastava, Egor Titovich, Jean-Luc Urbain, Verna Vanderpuye, Richard L Wahl, Jennifer S Yu, Mohamed Saad Zaghloul, Hongcheng Zhu, Andrew M Scott	
47.	[Comment] Spillover benefits of workforce capacity building in radiotherapy	Wilfred Ngwa, Twalib Ngoma	
48.	[Comment] Radiotherapy gaps and new frontiers in the Commonwealth	Mei Ling Yap, Danielle Rodin	
49.	[Comment] Radiotherapy and theranostics in a changing world	Cheryl Lai, Smriti Patodia, David Collingridge	
50.	[News] AACR highlights advances and threats to US cancer research	Tony Kirby	
51.	[News] President Biden taking Cancer Moonshot global	Sharmila Devi	
52.	[News] Organisations withdraw from cancer conference over tobacco link	Emma Wilkinson	
53.	[Policy Review] Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE	Philippe Morice, Giovanni Scambia, Nadeem R Abu-Rustum, Maribel Acien, Alessandro Arena, Sara Brucker, Ying Cheong, Pierre Collinet, Francesco Fanfani, Francesca Filippi, Ane Gerda Zahl Eriksson, Sebastien Gouy, Philipp Harter, Xavier Matias-Guiu, George Pados, Maja Pakiz, Denis Querleu, Alexandros Rodolakis, Christine Rousset-Jablonski, Artem Stepanyan, Antonia Carla Testa, Kirsten Tryde Macklon, Dimitrios Tsolakidis, Michel De Vos, François Planchamp, Michaël Grynberg	

更新于 8 分钟前

近期历史最近 100 条记录

2024-10-29	[Policy Review] Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements	Javier E Villanueva-Meyer, Spyridon Bakas, Pallavi Tiwari, Janine M Lupo, Evan Calabrese, Christos Davatzikos, Wenya Linda Bi, Marwa Ismail, Hamed Akbari, Philipp Lohmann, Thomas C Booth, Benedikt Wiestler, Hugo J W L Aerts, Ghulam Rasool, Joerg C Tonn, M	
2024-10-29	[Articles] Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data	Marie Lund, Giulia Corn, Maj-Britt Jensen, Tonny Petersen, Kim Dalhoff, Bent Ejlertsen, Lars Køber, Jan Wohlfahrt, Mads Melbye	
2024-10-29	[Policy Review] Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice	Spyridon Bakas, Philipp Vollmuth, Norbert Galldiks, Thomas C Booth, Hugo J W L Aerts, Wenya Linda Bi, Benedikt Wiestler, Pallavi Tiwari, Sarthak Pati, Ujjwal Baid, Evan Calabrese, Philipp Lohmann, Martha Nowosielski, Rajan Jain, Rivka Colen, Marwa Ismail,	
2024-10-29	[Correspondence] PSMA-PET research: addressing challenges and prospects – Authors' reply	Boris A Hadaschik, Madeleine J Karpinski, Johannes Hüsing, Wolfgang P Fendler	
2024-10-29	[Editorial] Caring for carers of people with cancer	The Lancet Oncology	
2024-10-29	[Articles] Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial	Mafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, Erika Hamilton, Yaroslav Kulyaba, Timur Andabekov, Yevhen Hotko, Tamar Melkadze, Gia Nemsadze, Patrick Neven, Vladimir Vladimirov, Claudio Zamagni, Hannelore Denys, Frédéric Forget, Zsolt Horvath, Alfiy	
2024-10-29	[Correspondence] Concerns regarding the AtTEnd trial in advanced endometrial carcinoma	Queran Lin, Wenyi Jin, Dan Shan	
2024-10-29	[Correspondence] PSMA-PET research: addressing challenges and prospects	Hantong Hu	
2024-10-29	[Correspondence] PSMA-PET research: addressing challenges and prospects	Dan Shan	
2024-10-29	[Correspondence] Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer?	Ryan Huey, Kanwal Raghav	
2024-10-29	[Correspondence] Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer? – Authors' reply	Xichun Hu, Shiyu Jiang, Xin Liu	
2024-10-29	[Correspondence] Celiac plexus radiosurgery for retroperitoneal pain syndrome – Authors' reply	Yaacov R Lawrence, Ronen Fluss, Laurence S Freedman, Zvi Symon	
2024-10-29	[Correspondence] Celiac plexus radiosurgery for retroperitoneal pain syndrome	Ertugrul Senturk, Serap Catli Dinc	
2024-10-29	[Corrections] Correction to Lancet Oncol 2024; 25: 1453–64		
2024-10-29	[Correspondence] Concerns regarding the AtTEnd trial in advanced endometrial carcinoma	Ze Xiang, Jian Wu	
2024-10-29	[Comment] The state of the science of oral selective oestrogen receptor degraders	Kristina Fanucci, Erica L Mayer	
2024-10-29	[Corrections] Correction to Lancet Oncol 2024; 25: 1325–36		
2024-10-29	[Correspondence] [18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer – Authors' reply	Sébastien Thureau, Philippe Giraud, Gérard Zalcman, Pierre Vera	
2024-10-29	[Correspondence] Concerns regarding the AtTEnd trial in advanced endometrial carcinoma – Authors' reply	Elena Biagioli, Eliana Rulli, Roldano Fossati, Nicoletta Colombo	
2024-10-29	[Correspondence] [18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer	Sarah Bowen Jones, Saskia Cooke, José Belderbos, Corinne Faivre-Finn	
2024-10-29	[Correspondence] [18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer	Xiaoling Xu, Lisha Ye, Jinpeng Shi, Huihui Li, Yong Fang	
2024-10-29	[Correspondence] Omitting study limitations might have implications for the patients – Authors' reply	Jean-Yves Blay, Sylvie Chabaud, David Perol, Axel Le Cesne	
2024-10-29	[Correspondence] Omitting study limitations might have implications for the patients	Paul de Boissieu, Sylvie Chevret	
2024-10-29	[Articles] Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis	Antonio D'Alessio, Bernardo Stefanini, Julia Blanter, Benjamin Adegbite, Fionnuala Crowley, Vincent Yip, Sarah Slater, Claudia Angela Maria Fulgenzi, Ciro Celsa, Giulia Francesca Manfredi, Madhava Pai, Robert D Goldin, Stephen C Ward, Maria Isabel Fiel, D	
2024-10-29	[News] US legislation might soon allow easier access to cancer medications	Karl Gruber	
2024-10-29	[News] Renewed collaboration aims to improve cancer outcomes in South America	Manjulika Das	
2024-10-29	[Perspectives] Cancer control in the Commonwealth: a roadmap	Rifat Atun, Bhawna Sirohi, Che Reddy, Mary Gospodarowicz	
2024-10-29	[Articles] Access to diagnostic imaging and radiotherapy technologies for patients with cancer in the Baltic countries, eastern Europe, central Asia, and the Caucasus: a comprehensive analysis	Manjit Dosanjh, Vesna Gershan, Eugenia C Wendling, Jamal S Khader, Taofeeq A Ige, Mimoza Ristova, Richard Hugtenburg, Petya Georgieva, C Norman Coleman, David A Pistenmaa, Gohar H Hovhannisyan, Tatul Saghatelyan, Kamal Kazimov, Rovshan Rzayev, Gulam R Bab	
2024-10-29	[Articles] Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial	Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García Campelo, Joaquín Casal, Manuel Dómine, Bartomeu Massuti, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier de Castro, David Gómez de Antonio, Iván Macia, Santiago Figueroa, Lu	
2024-10-29	[Personal View] Interchangeability of immune checkpoint inhibitors: an urgent need for action	Michiel Zietse, Roelof W F van Leeuwen, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Jolanda E de Boer, Rudy Dupree, Ron H J Mathijssen, Lonneke Timmers	
2024-10-29	[Corrections] Correction to Lancet Oncol 2024; 25: 1310–24		
2024-10-29	[News] UK NHS cancer patients to be among those benefiting from deal with life sciences industry	Tony Kirby	
2024-10-29	[News] The Biden administration curbs cancer drug costs for Medicare patients	Bryant Furlow	
2024-10-29	[News] Abortion restrictions have a negative impact on cancer care	Sharmila Devi	
2024-10-29	[Comment] The hidden barriers to using cancer registration data	Nicola Hughes, Richard Feltbower, Dan Stark	
2024-10-29	[Articles] Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis	Ashley Jackson, Pradeep S Virdee, Sharon Tonner, Jason L Oke, Rafael Perera, Kaveh Riahi, Ying Luan, Sara Hiom, Harpal Kumar, Harit Nandani, Kathryn N Kurtzman, Dyfed Huws, Dawn Allan, Stephanie Smits, Sean McPhail, Eileen E Parkes, F D Richard Hobbs, Mar	
2024-10-29	[Articles] Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis	Harriet Rumgay, Suzanne T Nethan, Richa Shah, Jérôme Vignat, Olalekan Ayo-Yusuf, Pankaj Chaturvedi, Eliete N S Guerra, Prakash C Gupta, Ruchika Gupta, Shiwei Liu, Cecilia Magnusson, Mark Parascandola, Yvette C Paulino, Negar Rezaei, Kamran Siddiqi, Saman	
2024-10-29	[News] ASTRO 2024 Annual Meeting	Smriti Patodia	
2024-10-29	[Articles] Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy study	Dianna L Ng, Edda Vuhahula, Asteria H Kimambo, Marie Claire Ndayisaba, Godfrey S Philipo, Beatrice P Mushi, Kenneth E Ho, Alan Paciorek, Zainab Illonga, Li Zhang, Poonam Vohra, Jodi Weidler, Michael Bates, Elia J Mmbaga, Katherine Van Loon	
2024-10-29	[News] Jordan joins the Global Platform for Access to Childhood Cancer Medicines	Elizabeth Gourd	
2024-10-29	[News] Approval of single-use e-cigarettes ban in France	Manjulika Das	
2024-10-29	[Corrections] Correction to Lancet Oncol 2024; 25: 1371–86		
2024-10-29	[Corrections] Correction to Lancet Oncol 2024; 25: 1357–70		
2024-10-29	[Comment] Focus where it matters: turning insights into advocacy	John Christodouleas, Therese Lindé, Gustaf Salford	
2024-10-29	[Comment] Radiotherapy and conflict: from disruption to expansion and hope	Nazik Hammad, Fidel Rubagumya	
2024-10-29	[The Lancet Oncology Commission] Radiotherapy and theranostics: a Lancet Oncology Commission	May Abdel-Wahab, Francesco Giammarile, Mauro Carrara, Diana Paez, Hedvig Hricak, Nayyereh Ayati, Jing Jing Li, Malina Mueller, Ajay Aggarwal, Akram Al-Ibraheem, Sondos Alkhatib, Rifat Atun, Abubakar Bello, Daniel Berger, Roberto C Delgado Bolton, John M B	
2024-10-29	[Comment] Spillover benefits of workforce capacity building in radiotherapy	Wilfred Ngwa, Twalib Ngoma	
2024-10-29	[Comment] Radiotherapy gaps and new frontiers in the Commonwealth	Mei Ling Yap, Danielle Rodin	
2024-10-29	[Comment] Radiotherapy and theranostics in a changing world	Cheryl Lai, Smriti Patodia, David Collingridge	
2024-10-29	[News] AACR highlights advances and threats to US cancer research	Tony Kirby	
2024-10-29	[News] Organisations withdraw from cancer conference over tobacco link	Emma Wilkinson	
2024-10-29	[News] President Biden taking Cancer Moonshot global	Sharmila Devi	
2024-10-29	[Policy Review] Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE	Philippe Morice, Giovanni Scambia, Nadeem R Abu-Rustum, Maribel Acien, Alessandro Arena, Sara Brucker, Ying Cheong, Pierre Collinet, Francesco Fanfani, Francesca Filippi, Ane Gerda Zahl Eriksson, Sebastien Gouy, Philipp Harter, Xavier Matias-Guiu, George	
2024-10-01	[Clinical Picture] IVLBCL mimicking VEXAS syndrome	Kevin Shopsowitz, Alym Abdulla, Habib Moshref Razavi	
2024-10-01	[Editorial] Reviving the UK NHS: Labour's biggest challenge?	The Lancet Oncology	
2024-10-01	[Review] Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies	Foram Khatsuria, Christel McMullan, Olalekan Lee Aiyegbusi, Karen L Shaw, Roshina Iqbal, Francesca Kinsella, Keith Wilson, Lester Pyatt, Marlene Lewis, Sophie M R Wheldon, David Burns, Ronjon Chakraverty, Melanie Calvert, Sarah E Hughes	
2024-10-01	[Articles] Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial	Eunice S Wang, Ghayas C Issa, Harry P Erba, Jessica K Altman, Pau Montesinos, Stephane DeBotton, Roland B Walter, Kristen Pettit, Michael R Savona, Mithun Vinod Shah, Marina Kremyanskaya, Maria R Baer, James M Foran, Gary Schiller, Lionel Adès, Mael Heibl	
2024-10-01	[Policy Review] Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sara	Zachary S Zumsteg, Siddharth Sheth, Salma K Jabbour, Krishnan R Patel, Randall J Kimple, Terence M Williams, Meng Xu-Welliver, Pedro A Torres-Saavedra, Arta M Monjazeb, Jyoti Mayadev, Steven E Finkelstein, John M Buatti, Sandip P Patel, Steven H Lin	
2024-10-01	[Perspectives] Using cancer to fuel art at the Edinburgh Festival Fringe	Peter Ranscombe	
2024-10-01	[Corrections] Correction to Lancet Oncol 2024; 25: 989–1002		
2024-10-01	[Perspectives] The Cancer Tapestry is telling a thousand stories	Peter Ranscombe	
2024-10-01	[Comment] Precision medicine with MET exon 14: a partial success	Quincy S-C Chu	
2024-10-01	[Correspondence] Adverse obstetric outcomes in female survivors of adolescent and young adult cancers	Yizhuan Huang, Han Wang	
2024-10-01	[Correspondence] Adverse obstetric outcomes in female survivors of adolescentand young adult cancers – Authors' reply	Raoul C Reulen, Ceren Sunguc, David L Winter, Gavin Rudge, Angela Polanco, Katherine A Birchenall, Melanie Griffin, W Hamish B Wallace, Richard A Anderson, Michael M Hawkins	
2024-10-01	[Correspondence] Adverse obstetric outcomes in female survivors of adolescent and young adult cancers	Weizhen Tang, Taihang Liu, Xia Lan	
2024-10-01	[Correspondence] Adverse obstetric outcomes in female survivors of adolescent and young adult cancers	Ying Cui	
2024-10-01	[Personal View] A brave new framework for glioma drug development	Kelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, Marjolein Geurts, Timothy F Cloughesy, Jason Huse, Elizabeth S Duke, Justin Lathia, David M Ashley, Edjah K Nduom, Georgina Long, Kirit Singh, Anthony Chalmers, Manmeet S Ahluwalia, Amy Heimberger, S	
2024-10-01	[Personal View] The tyranny of non-inferiority trials	Ian F Tannock, Marc Buyse, Mickael De Backer, Helena Earl, Daniel A Goldstein, Mark J Ratain, Leonard B Saltz, Gabe S Sonke, Garth W Strohbehn	
2024-10-01	[Comment] Diagnostic accuracy of risk prediction models in postmenopausal patients with suspected ovarian cancer	Cagatay Taskiran, Muhterem Melis Canturk	
2024-10-01	[Articles] Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study	Sudha Sundar, Ridhi Agarwal, Clare Davenport, Katie Scandrett, Susanne Johnson, Partha Sengupta, Radhika Selvi-Vikram, Fong Lien Kwong, Sue Mallett, Caroline Rick, Sean Kehoe, Dirk Timmerman, Tom Bourne, Ben Van Calster, Hilary Stobart, Richard D Neal, Us	
2024-10-01	[Correspondence] Investigating hidden influences on treatment for gastrointestinal stromal tumours with AI: diet, chronic conditions, and mental health	Hanjun Ma, Shibo Zhao, Mingxuan Liu, Qunqiang Luo	
2024-10-01	[Articles] Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial	Jürgen Wolf, Maximilian Hochmair, Ji-Youn Han, Noemi Reguart, Pierre-Jean Souquet, Egbert F Smit, Sergey V Orlov, Johan Vansteenkiste, Makoto Nishio, Maja de Jonge, Wallace Akerley, Edward B Garon, Harry J M Groen, Daniel S W Tan, Takashi Seto, Garrett M	
2024-10-01	[Correspondence] Investigating hidden influences on treatment for gastrointestinal stromal tumours with AI: diet, chronic conditions, and mental health – Authors' reply	Georgios Antonios Margonis, Dimitris Bersimas, Samuel Singer	
2024-10-01	[Comment] A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer	Angela Y Jia, Daniel E Spratt	
2024-10-01	[Correspondence] NHS cancer services and systems: critical support for cancer care	David Stewart Morrison, Kathryn Puxty	
2024-10-01	[Perspectives] Losing my brother, finding myself	Jules Morgan	
2024-10-01	[Personal View] Best practices and novel approaches for the preclinical development of drug–radiotherapy combinations for cancer treatment	Pataje G S Prasanna, Mansoor M Ahmed, Julie A Hong, C Norman Coleman	
2024-10-01	[News] Families of cancer victims wait for benefits decades after the World Trade Center attack	Karl Gruber	
2024-10-01	[News] ESMO Congress 2024	Cheryl Lai	
2024-10-01	[Articles] Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study	Arun A Azad, Mathias Bressel, Hsiang Tan, Mark Voskoboynik, Aneta Suder, Andrew J Weickhardt, Alexander Guminski, Roslyn J Francis, Javad Saghebi, Nattakorn Dhiantravan, Anthony M Joshua, Louise Emmett, Lisa Horvath, Declan G Murphy, Edward Hsiao, Bavanth	
2024-10-01	[Articles] Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study	Othon Iliopoulos, Ane B Iversen, Vivek Narayan, Benjamin L Maughan, Kathryn E Beckermann, Stephane Oudard, Tobias Else, Jodi K Maranchie, Cynthia Muller Goldberg, Wei Fu, Rodolfo F Perini, Yanfang Liu, W Marston Linehan, Ramaprasad Srinivasan, Eric Jonasc	
2024-10-01	[News] Petition to end travel insurance discrimination against people with cancer	Manjulika Das	
2024-10-01	[News] Rising costs of cancer medicines	Sharmila Devi	
2024-10-01	[Articles] Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial	Zikun Peng, Huayi Li, Yunong Gao, Li Sun, Jie Jiang, Bairong Xia, Yi Huang, Yu Zhang, Yu Xia, Yuxin Zhang, Yiyang Shen, Bowen Huang, Jiayu Nie, Xinrong Chen, Xingyu Liu, Cui Feng, Zhen Li, Wei Zhang, Kangjia Tao, Qiuxue Zhang, Shican Duan, Yaheng Chen, Ye	
2024-10-01	[Articles] Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial	Alessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani, Marina Motta, Gianluca Gaidano, Giulia Quaresmini, Lydia Scarfò, Gioacchino Catania, Marina Deodato, Rebecca Jones, Valentina Tabanelli, Valen	
2024-10-01	[Articles] [89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial	Brian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, Michael A Morris, Viraj Master, Andrew M Scott, Charles van Praet, Clement Bailly, Bülent Önal, Tamer Aksoy, Robin Merkx, David M Schuster, Sze Ting Lee, Neeta Pandit-Taskar, Alice C Fan, Phillip All	
2024-10-01	[Comment] Treatment of Richter transformation—immunotherapy to the rescue?	Othman Al-Sawaf, Barbara Eichhorst	
2024-10-01	[Articles] Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study	Laura A Dawson, Jolie Ringash, Alysa Fairchild, Paul Stos, Kristopher Dennis, Aamer Mahmud, Teri Lynn Stuckless, Francois Vincent, David Roberge, Matthew Follwell, Raimond K W Wong, Derek J Jonker, Jennifer J Knox, Camilla Zimmermann, Philip Wong, Aisling	
2024-10-01	[News] New developments in tobacco control measures in Europe	Talha Burki	
2024-10-01	[News] European Commission approval for Dutch investment in radiopharmaceuticals	Karl Gruber	
2024-10-01	[Comment] Radiation oncology: a call for papers for ESTRO 2025	David Collingridge, Pierre Blanchard	
2024-10-01	[News] World's first lung cancer vaccine trial launched in the UK	Elizabeth Gourd	
2024-10-01	[News] Continued suboptimal HPV vaccine coverage in the USA	Talha Burki	
2024-10-01	[News] Medicare drug price negotiations by the US Government	Sharmila Devi	
2024-10-01	[Comment] The UK needs to be a leader, not a lagger, in the global cancer effort	Mark Lawler, Ajay Aggarwal, Julie Gralow, Richard Sullivan, Pat Price	
2024-10-01	[Articles] Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis	Yi Zhao, Ying He, Wei Wang, Qi Cai, Fan Ge, Zisheng Chen, Jianqi Zheng, Yuan Zhang, Hongsheng Deng, Ying Chen, Shen Lao, Hengrui Liang, Wenhua Liang, Jianxing He	
2024-08-28	[Clinical Picture] Multimodality imaging of a large incidental papillary fibroelastoma	Wiaam Elkhatib, Prajwal Reddy	
2024-08-28	[Editorial] Legacies of conflict and humanitarian crises on cancer care	The Lancet Oncology	
2024-08-28	[Policy Review] Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup	Carien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, Emma Allanson, Lauriane Eberst, Se Ik Kim, Remi A Nout, Jeong-Yeol Park, Domenica Lorusso, Linda Mileshkin, Petronella B Ottevanger, Alison Brand, Delia Mezzanzanica, Amit Oza, Val Gebski, Bhavana Pothur	
2024-08-28	[Review] The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group	Philipp Karschnia, Jasper K W Gerritsen, Nico Teske, Daniel P Cahill, Asgeir S Jakola, Martin van den Bent, Michael Weller, Oliver Schnell, Einar O Vik-Mo, Niklas Thon, Arnaud J P E Vincent, Michelle M Kim, Guido Reifenberger, Susan M Chang, Shawn L Herve	